These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 16627756

  • 1. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
    Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F.
    Blood; 2006 Sep 01; 108(5):1478-84. PubMed ID: 16627756
    [Abstract] [Full Text] [Related]

  • 2. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
    Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 1):68-75. PubMed ID: 14734453
    [Abstract] [Full Text] [Related]

  • 3. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 4. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2584-92. PubMed ID: 15493041
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Dalziel K, Round A, Stein K, Garside R, Price A.
    Health Technol Assess; 2004 Jul 01; 8(28):iii, 1-120. PubMed ID: 15245690
    [Abstract] [Full Text] [Related]

  • 6. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group.
    N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335
    [Abstract] [Full Text] [Related]

  • 7. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
    Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M.
    Blood; 2004 Oct 01; 104(7):1979-88. PubMed ID: 15198956
    [Abstract] [Full Text] [Related]

  • 8. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J.
    Blood; 2006 Sep 15; 108(6):1835-40. PubMed ID: 16709931
    [Abstract] [Full Text] [Related]

  • 9. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [Abstract] [Full Text] [Related]

  • 10. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
    Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG.
    Haematologica; 2009 Dec 01; 94(12):1669-75. PubMed ID: 19648168
    [Abstract] [Full Text] [Related]

  • 16. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS, Wang YY, Zhao YZ, Yi SH, Qian LS, Wang GR, Yu Z, Wang Y, Wang JX, Qiu LG.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb 01; 18(1):208-12. PubMed ID: 20137149
    [Abstract] [Full Text] [Related]

  • 17. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
    Marin D, Marktel S, Szydlo R, Klein JP, Bua M, Foot N, Olavarria E, Shepherd P, Kanfer E, Goldman JM, Apperley JF.
    Lancet; 2003 Aug 23; 362(9384):617-9. PubMed ID: 12944062
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2574-83. PubMed ID: 15493042
    [Abstract] [Full Text] [Related]

  • 19. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D.
    Ther Umsch; 2006 Apr 01; 63(4):249-54. PubMed ID: 16689455
    [Abstract] [Full Text] [Related]

  • 20. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 Apr 01; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.